Edication Imply no. of drugs prescribed CNSDose Singh et al, 201565 Medication dosing unique from usual practicea 65 NA NA 76.8 53 Mean 1.9 44.1 58 Mean 1.7 .001 .66 .27 Measure PGx TAU P ValueAbbreviations: NA, not applicable, PGx, pharmacogenomic-guided testing; TAU, Bradykinin Receptor site Treatment as usual. a Definition not specified by study.SUBGROUPS BY BASELINE MEDICATION CLASSIFICATION AND TEST RESULTSSeveral research reported on alterations in medication choice or varieties of medications provided depending on baseline genetic test results and congruency with baseline medications (Table 9). Studies showing the PKD2 manufacturer proportion of patients taking congruent medications at follow-up recommend prescribing patterns that differ amongst groups, but do not necessarily indicate that a lot more adjustments occurred in either group, rather that clinicians were following the test final results.Ontario Health Technologies Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugustTable 9: Treatment Choice Based on Genetic Test Classification for PGx Versus TAUAuthor, Year (Main Study) GeneSight Greden et al, 201857 Forester et al, 201967 (Greden et al, 201857) Thase et al, 201968(Greden 201857) Taking congruent medications at follow-up (green or yellow bin)a Distribution of medication’s genedrug interaction severity category at follow-up (aged 65 y) Medication switch among those in yellow or red bin at baselinea,b,c Taking congruent medicines at follow-up (green bin) among those in yellow or red bin at baselinea,b Switched, augmented, or doseadjusted amongst these in red bin at baselinea,b Switched, augmented, or doseadjusted amongst those in red bin at baselinea,b Taking greena bin medication at follow-up Hall-Flavin et al, 201256 Neuropharmagen Perez et al, 201762 Unspecified Test Shan et al, 201963 Prescribed medicines in “Use as directed” category Prescribed medicines in “Use with caution” category Prescribed medicines in “Use with improved caution and more frequent monitoring” category NR 3.two 0 37.five 40 22.5 NR NR NR Prescribed medicines in disagreement with test outcome 17 participants NA NA Distinction in prescribing patterns at follow-up Baseline: 79.four Follow-up: 91.2 Green bina: 59.7 Yellow bina: 26.0 Red bina: 14.3 65.8 66.4 Baseline: 77.5 Follow-up: 76.3 Green bina: 25.0 Yellow bina: 50.0 Red bina: 25.0 52.3 20 NR Overall .001 Proportion ( ) Measure PGx TAU P Worth .001 NRWinner et al, 201365 Hall-Flavin et al,.93.55..40 Green bina: NE Yellow bina: NE Red bina: 5.27.6 Green bina: NE Yellow bina: NE Red bina: 21.NS General .Abbreviations: NA, not applicable; NE, not estimable; NR, not reported; NS, not substantial; PGx, pharmacogenomic-guided treatment; TAU, treatment as usual. a Medicines were categorized as green bin (use as directed), yellow bin (use with caution), or red bin (use with enhanced caution and much more frequent monitoring). b Medication switch was defined as dropping a medication and adding a distinct medication during very first 8 weeks. c Analysis deemed only persons taking a minimum of 1 medication on test report.Ontario Health Technology Assessment Series; Vol. 21: No. 13, pp. 114, AugustAugust 2021 GeneSightAll principal GeneSight research evaluated various measures of therapeutic choices determined by baseline medication genetic classification or the proportion taking medicines considered to be genetically congruent at follow-up. Greden et al57 identified a comparable proportion of individuals were taking medicines deemed to become genetically congruent with tes.